Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Long-Term Safety of Briquilimab for Patients with Chronic Urticaria

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the long-term safety and effects of a treatment called Briquilimab for people with Chronic Urticaria. Chronic Urticaria is a condition where the skin develops itchy hives or welts that last for more than six weeks. The treatment being tested, Briquilimab, is given as an injection under the skin and is a type of medication known as a monoclonal antibody, which is a protein designed to target specific parts of the immune system.

The purpose of this study is to evaluate how safe Briquilimab is and how well it works over a longer period. Participants in this study will have previously taken part in other trials sponsored by Jasper Therapeutics, the company behind Briquilimab. During the study, participants will receive regular injections of Briquilimab and will be monitored for any side effects or changes in their condition. The study will help researchers understand how Briquilimab affects the symptoms of Chronic Urticaria over time.

Throughout the study, participants will undergo regular check-ups and assessments to track their progress and any potential side effects. The study aims to provide valuable information on the long-term use of Briquilimab for managing Chronic Urticaria, contributing to the development of effective treatments for this persistent skin condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, participants must have previously completed an eligible Jasper-sponsored clinical trial within the last 4 months without experiencing any severe allergic reactions related to the investigational product.

    Participants must provide informed written consent before proceeding with the study.

  2. Step 2

    Eligibility confirmation

    Eligibility is confirmed by ensuring that laboratory parameters are within acceptable ranges, such as hemoglobin levels, platelet count, and liver function tests.

    Participants must agree to abstain from blood donations during the trial period.

  3. Step 3

    Medication administration

    The medication used in this study is briquilimab, administered as a subcutaneous injection.

    The frequency and duration of administration will be determined by the study protocol and communicated to participants during the trial.

  4. Step 4

    Monitoring and assessments

    Participants will undergo regular monitoring to evaluate the safety and tolerability of briquilimab.

    Assessments will include physical examinations and standard clinical laboratory tests to track any adverse events.

  5. Step 5

    Evaluation of clinical activity

    The study aims to evaluate the long-term clinical activity of briquilimab in managing chronic urticaria.

    Participants with chronic inducible urticaria will have their critical temperature and friction thresholds measured over time.

    Participants with chronic spontaneous urticaria will have their urticaria activity and control scores assessed over time.

  6. Step 6

    Completion of the study

    The study is estimated to conclude by December 7, 2029.

    Participants will be informed of the study's findings and any relevant follow-up actions upon completion.

Who can join the trial?

13 criteria

  • Participants must provide informed written consent, meaning they agree to join the study after understanding what it involves.
  • Participants must have previously taken part in and completed an eligible Jasper-sponsored clinical trial in the last 4 months without having any serious allergic reaction related to the study treatment.
  • For those with **Chronic Spontaneous Urticaria (CSU)**, they must have a **UAS7** score of 16 or higher after at least 8 weeks of safety follow-up in the previous study, or they must have completed the previous study regardless of their UAS7 score. **UAS7** is a way to measure the severity of urticaria symptoms over a week.
  • For those with **Chronic Inducible Urticaria (CIndU)**, such as **cold contact urticaria** or **symptomatic dermographism**, they must have a **UCT** score of 12 or less after at least 8 weeks of safety follow-up in the previous study, or they must have completed the previous study regardless of their UCT score. **UCT** is a way to measure how well urticaria is controlled.
  • Participants must have certain blood test results within acceptable ranges, including:
    • **Hemoglobin**: 10 grams per deciliter (g/dL) or more. Hemoglobin is a protein in red blood cells that carries oxygen.
    • **Platelets**: 100,000 per cubic millimeter (mm³) or more. Platelets help with blood clotting.
    • **Neutrophils**: 1,500 per cubic millimeter (mm³) or more. Neutrophils are a type of white blood cell important for fighting infections.
    • **Alanine aminotransferase (ALT)** or **aspartate aminotransferase (AST)**: Less than 3 times the upper limit of normal. These are liver enzymes.
    • **Serum total bilirubin**: Less than 2 times the upper limit of normal, unless due to **Gilbert’s syndrome**, a common and harmless liver condition.
    • **Estimated creatinine clearance (eCrCl)**: 30 milliliters per minute (mL/min) or more, which measures kidney function.
    • Participants must agree not to donate blood while participating in the trial, from the start to the end of the trial.
    • Male participants who are not surgically sterilized (not had a vasectomy) and are sexually active with women must use highly effective birth control methods and must not donate sperm during the trial and for at least 150 days after the last dose of the study drug. A vasectomy is a surgical procedure for male sterilization.
    • Female participants who can have children and are sexually active with men must use highly effective birth control methods during the trial and for at least 90 days after the last dose of the study drug. Women who cannot have children must be surgically sterile (had a complete removal of the uterus, ovaries, or fallopian tubes) or be in menopause (no menstrual periods for at least 1 year).

Who cannot join the trial?

8 criteria

  • Patients who are not within the specified age range for the study.
  • Patients who have medical conditions other than Chronic Urticaria, which is a condition that causes hives or itchy welts on the skin.
  • Patients who are not able to follow the study procedures or instructions.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial recently.
  • Patients who have a history of severe allergic reactions.
  • Patients who are taking medications that might interfere with the study.
  • Patients who have any other health issues that the study doctors think might make it unsafe for them to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Briquilimab is a medication being studied for its long-term safety and effectiveness in treating chronic urticaria, which is a condition characterized by persistent hives. The trial aims to understand how well patients tolerate this medication over an extended period.

What is already known about the treatment

Briquilimab – This medication is administered through an injection, typically under the skin. It is currently being studied in clinical trials to assess its long-term safety and effectiveness, particularly for treating chronic urticaria, a condition characterized by persistent hives. Briquilimab works by targeting specific molecules in the immune system to reduce inflammation and allergic reactions. It is classified as a monoclonal antibody, which is a type of medication designed to interact with specific proteins in the body to modify immune responses.

Investigated diseases

Chronic Urticaria – Chronic urticaria is a condition characterized by the presence of hives, which are red, itchy welts on the skin that can vary in size and appear anywhere on the body. These hives can persist for six weeks or longer and may occur with or without an identifiable trigger. The condition is often divided into two types: chronic spontaneous urticaria, where hives appear without a known cause, and chronic inducible urticaria, where hives are triggered by specific factors such as temperature or pressure. The hives can cause significant discomfort and may be accompanied by swelling, known as angioedema, particularly around the eyes and lips. The severity and frequency of the hives can vary, and they may come and go over time.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-517830-17-00Protocol codeJSP-CP-014Estimated enrolment90 patientsSponsorJasper Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.